Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0344307 (analgesia)
 28,200 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The use of opioids for the relief of pain and headache disorders has been studied for years. Nowadays, particularly because of its ability to produce analgesia in various pain models, delta opioid receptor (DOPr) emerges as a promising target for the development of new pain therapies. Indeed, their potential to avoid the unwanted effects commonly observed with clinically used opioids acting at the mu opioid receptor (MOPr) suggests that DOPr agonists could be a therapeutic option. In this review, we discuss the use of opioids in the management of pain in addition to describing the evidence of the analgesic potency of DOPr agonists in animal models.
 ...
PMID:Alleviating pain with delta opioid receptor agonists: evidence from experimental models. 3218 76

In present study, multi-target and multi-pathway mechanisms of Jasminum lanceolarium Roxb (JL) on primary dysmenorrhea (PDM) treatment were predicted by the approach of network pharmacology and molecular docking, leading to the obtaining of 22 predicted targets for 69 compounds in JL. The Compound-Target analysis displayed intimate association among targets and compounds. Meanwhile, the Compound-Target-Target revealed PTGS2, OPRD1 and NOS3 were the key targets with intensive interaction. The Compound-Target-Pathway network indicated these pathways were closely related to hormone regulation, central analgesia, spasmolysis and inflammation. The anti-inflammation pathways might be the key mechanism of JL for the treatment of PDM based on KEGG pathway enrichment analysis and pharmacological experiment, and 10-hydroxyoleoside dimethyl ester might be a promising leading compound due to its good molecular docking scores and previous experimental evaluation.
 ...
PMID:Virtual screening of active compounds from jasminum lanceolarium and potential targets against primary dysmenorrhea based on network pharmacology. 3269 16

Opioids are the most effective analgesics used in the clinical management of cancer pain or non-cancer pain. However, chronic opioids therapy can cause many side effects including respiratory depression, nausea, sedation, itch, constipation, analgesic tolerance, hyperalgesia, high addictive potential, and abuse liability. Opioids exert their effects through binding to the opioid receptors belonging to the G-protein coupled receptors (GPCRs) family, including mu opioid receptor (MOR), delta opioid receptor (DOR), and kappa opioid receptor (KOR). Among them, MOR is essential for opioid-induced analgesia and also responsible for adverse effects of opioids. Importantly, MOR can form heterodimers with other opioid receptors and non-opioid receptors in vitro and in vivo, and has distinct pharmacological properties, different binding affinities for ligands, downstream signaling, and receptor trafficking. This mini review summarized recent progress on the function of Mu opioid receptor heterodimers, and we proposed that targeting mu opioid receptor heterodimers may represent an opportunity to develop new therapeutics, especially for chronic pain treatment.
 ...
PMID:Mu Opioid Receptor Heterodimers Emerge as Novel Therapeutic Targets: Recent Progress and Future Perspective. 3276 Feb 81


<< Previous 1 2 3 4 5 6 7 8